Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5-flourouracil · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| gefitinib | DRUG | - |
| cisplatin | DRUG | - |
| 5-flourouracil | DRUG | - |
Inclusion Criteria: * Provision of written informed consent * Patients with histologically proven primary SCCHN * Aged 18 or over Exclusion Criteria: * Patients eligible for surgery with curative intent * Other co-existing malignancies diagnosed within the last 5 years with the exception of basal...
5-flourouracil is used for squamous cell cancer, including cancer of the head and neck. It is being studied in a Phase 2 clinical trial for these conditions. The drug is an oncology small molecule being developed by AstraZeneca PLC.
AstraZeneca PLC (ticker: AZN) is developing 5-flourouracil. The company is conducting a Phase 2 clinical trial of the drug for squamous cell cancer and head and neck cancer. The trial is completed and enrolled 64 participants.
5-flourouracil is in Phase 2 clinical development. It is an investigational drug being studied for squamous cell cancer and head and neck cancer. The Phase 2 trial has been completed, and the drug is not yet approved for any use.
5-flourouracil is associated with one completed Phase 2 trial, NCT00255476, titled "The IRESSA Novel Head and Neck Chemotherapy Evaluation Study." The trial enrolled 64 participants with squamous cell cancer and head and neck cancer in the United Kingdom.
5-flourouracil is not the same as IRESSA. The clinical trial NCT00255476, which studies 5-flourouracil, is named the IRESSA Novel Head and Neck Chemotherapy Evaluation Study. IRESSA is a separate drug being evaluated in combination with 5-flourouracil in this trial.